NCT02465801View on ClinicalTrials.gov

Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein

PHASE2CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

December 16, 2014

Primary Completion Date

December 23, 2015

Study Completion Date

April 26, 2016

Conditions
Chemotherapy-induced Neutropenia
Interventions
DRUG

HSA-GCSF 1.2 mg

Human Serum Albumin GCSF 1.2mg at day 3 and Day 7

DRUG

HSA-GCSF 1.5 mg

Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7

DRUG

GCSF

GCSF 5 mcg/kg/day

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Scienses, Beijing

All Listed Sponsors
lead

Tianjin SinoBiotech Ltd.

INDUSTRY

NCT02465801 - Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein | Biotech Hunter | Biotech Hunter